Bioforce Nanosciences Holdings annual shareholders’ equity
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bioforce Nanosciences Holdings Shareholders’ Equity Growth & History (BFNH)
Bioforce Nanosciences Holdings's shareholders’ equity was −$618,543 for fiscal 2025.
View full Bioforce Nanosciences Holdings company overviewBioforce Nanosciences Holdings annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$618,543 | $1.7M | — |
| 2024 | 2024-12-31 | −$2.3M | −$482,362 | — |
| 2023 | 2023-12-31 | −$1.8M | −$471,953 | — |
| 2022 | 2022-12-31 | −$1.3M | −$485,414 | — |
| 2021 | 2021-12-31 | −$861,863 | −$501,955 | — |
| 2020 | 2020-12-31 | −$359,908 | −$407,216 | — |
| 2019 | 2019-12-31 | $47,308 | $17,504 | +58.73% |
| 2018 | 2018-12-31 | $29,804 | $21,602 | +263.37% |
| 2017 | 2017-12-31 | $8,202 | — | — |
Bioforce Nanosciences Holdings quarterly shareholders’ equity
Q4.17
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.3M | $2.7M | — |
| Q1 2026 | 2026-03-31 | −$720,954 | −$459,712 | — |
| Q4 2025 | 2025-12-31 | −$618,543 | $1.7M | — |
| Q3 2025 | 2025-09-30 | −$499,938 | $1.7M | — |
| Q2 2025 | 2025-06-30 | −$384,023 | $1.7M | — |
| Q1 2025 | 2025-03-31 | −$261,242 | $1.7M | — |
| Q4 2024 | 2024-12-31 | −$2.3M | −$482,362 | — |
| Q3 2024 | 2024-09-30 | −$2.2M | −$473,612 | — |
| Q2 2024 | 2024-06-30 | −$2.1M | −$473,195 | — |
| Q1 2024 | 2024-03-31 | −$2.0M | −$472,761 | — |
| Q4 2023 | 2023-12-31 | −$1.8M | −$471,953 | — |
| Q3 2023 | 2023-09-30 | −$1.7M | −$472,278 | — |
| Q2 2023 | 2023-06-30 | −$1.6M | −$481,158 | — |
| Q1 2023 | 2023-03-31 | −$1.5M | −$483,011 | — |
| Q4 2022 | 2022-12-31 | −$1.3M | −$485,414 | — |
| Q3 2022 | 2022-09-30 | −$1.2M | −$491,380 | — |
| Q2 2022 | 2022-06-30 | −$1.1M | −$482,753 | — |
| Q1 2022 | 2022-03-31 | −$994,271 | −$489,284 | — |
| Q4 2021 | 2021-12-31 | −$861,863 | −$501,955 | — |
| Q3 2021 | 2021-09-30 | −$741,162 | −$503,819 | — |
| Q2 2021 | 2021-06-30 | −$627,302 | −$507,881 | — |
| Q1 2021 | 2021-03-31 | −$504,987 | −$512,276 | — |
| Q4 2020 | 2020-12-31 | −$359,908 | −$407,216 | — |
| Q3 2020 | 2020-09-30 | −$237,343 | −$285,697 | — |
| Q2 2020 | 2020-06-30 | −$119,421 | −$161,338 | — |
| Q1 2020 | 2020-03-31 | $7,289 | −$26,906 | −78.68% |
| Q4 2019 | 2019-12-31 | $47,308 | $17,504 | +58.73% |
| Q3 2019 | 2019-09-30 | $48,354 | $24,419 | +102.02% |
| Q2 2019 | 2019-06-30 | $41,917 | — | — |
| Q1 2019 | 2019-03-31 | $34,195 | — | — |
| Q4 2018 | 2018-12-31 | $29,804 | $21,602 | +263.37% |
| Q3 2018 | 2018-09-30 | $23,935 | — | — |
| Q4 2017 | 2017-12-31 | $8,202 | — | — |
Bioforce Nanosciences Holdings shareholders’ equity trends
Over the last five fiscal years, Bioforce Nanosciences Holdings's shareholders’ equity decreased from −$359,908 to −$618,543, a change of −$258,635. The latest reported quarter, Q2 2026, shows $2.3M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioforce Nanosciences Holdings source filings ↗